The patient underwent multimodal comprehensive treatment, including iodine-125 seed implantation at the pancreatic primary site, eight cycles of hepatic arterial infusion chemotherapy, PD-L1 inhibitor (Benmelstobart), and oral S-1 maintenance therapy. After treatment, the patient's liver metastases significantly decreased in size (partial response according to RECIST 1.1), CA19-9 levels dropped from 4141.57 U/mL to 58.64 U/mL, overall survival exceeded 15 months, and quality of life remained good (ECOG score 1). The MDT strategy, particularly the combination of local interventional therapy with systemic treatment and immunotherapy, can effectively control both the primary and metastatic lesions of advanced PDAC, significantly prolonging patient survival and providing valuable treatment references for similar cases.

4 days ago

Journal

CA 19-9 (Cancer antigen 19-9)

Andewei (benmelstobart)

14d

BACON: Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)

P2, N=40, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

14 days ago

New P2 trial

Focus V (anlotinib) • cyclophosphamide • Andewei (benmelstobart)

25d

Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial. (PubMed, Lancet Oncol)

Benmelstobart plus anlotinib showed longer progression-free survival than pembrolizumab plus placebo and no unexpected safety signals were reported, suggesting benmelstobart plus anlotinib as a potential first-line option in driver gene-negative, PD-L1-positive, advanced NSCLC. Longer term follow-up is needed to establish effects on overall survival.

25 days ago

P3 data • Journal

PD-L1 (Programmed death ligand 1)

PD-L1 expression • PD-L1 negative

Keytruda (pembrolizumab) • Focus V (anlotinib) • Andewei (benmelstobart)

A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)

P3, N=578, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University

1 month ago

New P3 trial

TP53 (Tumor protein P53) • FAT1 (FAT atypical cadherin 1) • NOTCH3 (Notch Receptor 3)

TP53 mutation

cisplatin • paclitaxel • Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi) • Andewei (benmelstobart)

Anlotinib and Benmelstobart in DTC (clinicaltrials.gov)

P2, N=23, Not yet recruiting, Fudan University | Initiation date: Oct 2025 --> Apr 2026

1 month ago

Trial initiation date

Focus V (anlotinib) • Andewei (benmelstobart)

2ms

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients (clinicaltrials.gov)

P2, N=56, Recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

5-fluorouracil • Focus V (anlotinib) • Andewei (benmelstobart) • Onivyde (nanoliposomal irinotecan)

2ms

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma (clinicaltrials.gov)

P3, N=412, Not yet recruiting, Sun Yat-sen University

2 months ago

New P3 trial

cisplatin • gemcitabine • Focus V (anlotinib) • Andewei (benmelstobart)

2ms

Efficacy and Safety of Anlotinib plus Benmelstobart In Unresectable Anaplastic Thyroid Cancer: A Multicenter, Phase II, Single-arm Trial (ABATC Trial) (ChiCTR2500111580)

P2, N=60, Not yet recruiting, The First Affiliated Hospital, Sun Yat-sen University; The First Affiliated Hospital, Sun Yat-sen University

2 months ago

New P2 trial

Focus V (anlotinib) • Andewei (benmelstobart)

2ms

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=266, Recruiting, Beijing Tide Pharmaceutical Co., Ltd

2 months ago

New P1/2 trial

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • MSI-H/dMMR • BRAF mutation • NRAS mutation • RAS mutation • RET mutation • MET mutation

Lynparza (olaparib) • topotecan • Andewei (benmelstobart)

3ms

TQB2450-II-14: Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. (clinicaltrials.gov)

P2, N=71, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2024 --> Nov 2025 | Recruiting --> Terminated; Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.

3 months ago

Trial completion date • Trial termination • IO biomarker

carboplatin • gemcitabine • paclitaxel • docetaxel • Focus V (anlotinib) • doxorubicin hydrochloride • Andewei (benmelstobart)

3ms

Serum BDNF helps identify favorable subgroups in HCC patients treated with PD-L1 inhibitors and anti-angiogenic TKIs. (PubMed, Ther Adv Med Oncol)

We aimed to assess the efficacy, safety, and potential biomarkers of anlotinib plus TQB2450 in patients with advanced HCC. Elevated serum BDNF levels might serve as a potential positive prognostic marker and, together with ECOG score, may help complement the CRAFITY score in identifying subgroups that could benefit from ICIs and antiangiogenic therapy. This study was registered on ClinicalTrials.gov (NCT03825705, registered January 31, 2019).

3 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

AFP (Alpha-fetoprotein) • BDNF (Brain Derived Neurotrophic Factor) • CRP (C-reactive protein)

Focus V (anlotinib) • Andewei (benmelstobart)